What is the focus of Octapharma´s R&D and are there new products in the pipeline?

Octapharma remains dedicated to its mission "for the safe and optimal use of human proteins". As such, Octapharma will continue to specialise in the continuous improvement of human protein products (from human plasma and human cell lines) in order to extend its scientific lead and optimise the safety and user-friendliness of its products.

Octapharma’s recombinant Factor VIII product is currently in the final clinical trial phase and will soon be brought to the market.

Current Octapharma research projects include human-derived growth factor, fibrinogen, and recombinant granulocyte-colony stimulating factor, among others.

The core of Plasma Research & Development is in Vienna with additional laboratories in Germany. Recombinant Research and Development centres are located in Munich and Stockholm.